• 上海交通大學(xué)醫(yī)學(xué)院附屬瑞金醫(yī)院呼吸科( 上海 200025);

COPD 和肺癌均為最常見的吸煙相關(guān)呼吸道疾病。吸入性糖皮質(zhì)激素( ICS) 近年來被推薦用于重度COPD 的治療, 同時也被發(fā)現(xiàn)在肺癌的化學(xué)預(yù)防中起重要作用。本文通
過綜述ICS、COPD 和肺癌之間的關(guān)系, 特別是吸入糖皮質(zhì)激素在肺癌中的化學(xué)預(yù)防作用, 以期進一步明確ICS 在COPD和肺癌中的作用。

引用本文： 倪穎夢,時國朝. 吸入糖皮質(zhì)激素對COPD 患者肺癌的預(yù)防作用. 中國呼吸與危重監(jiān)護雜志, 2010, 9(3): 326-328. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國呼吸與危重監(jiān)護雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. 彭敏，李龍蕓.肺癌的早期診斷.中華內(nèi)科雜志，2003，42：884-886.
2. Papi A，Casoni G，Caramori G，et al.COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma.Thorax，2004，59：679-681.
3. Lung Health Study Research Group.Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.N Engl J Med，2000，343：1902-1909.
4. Pitty TL.Are COPD and lung cancer two manifestations of the same disease? Chest，2005，128：1895-1897.
5. Skillrud DM，Offord KP，Miller RD.Higher risk of lung cancer in chronic obstructive pulmonary disease：a prospective，matched，controlled study.Ann Intern Med，1986，105：503-507.
6. Pashko LL，Schwartz AG.Inhibition of 7，12-dimethylbenz[a]anthracene-induced lung tumorigenesis in A/J mice by food restriction is reversed by adrenalectomy.Carcinogenesis，1996，17：209-212.
7. Wattenberg LW，Estensen RD.Chemopreventive effects of myo-inositol and dexamethasone on benzo[a]pyrene and 4-（methylnitrosoamino）-1-（3-pyridyl）-1-butanone-induced pulmonary carcinogenesis in female A/J mice.Cancer Res，1996，56：5132-5135.
8. Pereira MA，Li YZ，Gunning WT，et al.Prevention of mouse lung tumors by budesonide and its modulation of biomarkers.Carcinogenesis，2002，23：1185-1192.
9. Wattenberg LW，Wiedmann TS，Estensen RD，et al.Chemoprevention of pulmonary carcinogenesis by aeosolized budesonide in female A/J mice.Cancer Res，1997，57：5489-5492.
10. Wattenberg LW，Wiedmann TS，Estensen RD，et al.Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol.Carcinogenesis，2000，21：179-182.
11. Lipkin M.Biomarkers of increased susceptibility to gastrointestinal cancer：new application to studies of cance prevention in human subjects.Cancer Res，1988，48：235-245.
12. Estensen RD，Jordan MM，Wiedmann TS，et al.Effect of chemoprevetive agents on separate stages of progression of benzo[a]pyrene induced lung tumors in A/J mice.Carcinogenesis，2004，25：197-201.
13. Parimon T，Chien JW，Bryson CL，et al.Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease.Am J Respir Crit Care Med，2007，175：712-719.
14. Miller YE，Keith RL.Inhaled corticosteroids and lung cancer chemoprevention.Am J Respir Crit Care Med，2007，175：636-637.
15. Lam S，leRiche JC，McWilliams A，et al.A randomized phase IIb Trial of pulmicort turbuhaler（budesonide） in people with dysplasia of the bronchial epithelium.Clin Cancer Res，2004，10：6502-6511.
16. Keith BD.Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy.BMC Cancer，2008，8：84.
17. Brody JS，Spira A.State of the art.Chronic obstructive pulmonary disease，inflammation，and lung cancer.Proc Am Thorac Soc，2006，3：535-537.
18. Pages V，F(xiàn)uchs RP.How DNA lesions are turned into mutations within cells? Oncogene，2002，21：8957-8966.
19. Barnes PJ.How corticosteroids control inflammation.Br J Pharmacol，2006，148：245-254.
20. John M，Au BT，Jose PJ，et al.Expression and release of interleukin-8 by human airway smooth muscle cells：inhibition by Th-2 cytokines and corticosteroids.Am J Respir Cell Mol Biol，1998，18：84-90.
21. Wissink S，van Heerde EC，vand der Burg B，et al.A dual mechanism mediates repression of NF-kappaB activity by glucocorticoids.Mol Endocrinol，1998，12：355-363.
22. Pereira MA，Tao LH，Wang W，et al.Chemoprevention：mouse colon and lung tumor bioassay and modulation of DNA methylation as a biomarker.Exp Lung Res，2005，31：145-163.
23. Counts JL，Goodman JI.Hypomethylation of DNA：a possible epigenetic mechanism involved in tumor promotion.Prog Clin Biol Res，1995，391：81-101.
24. Li L，Tao LH，Lubet RA，et al.Modulation by budesonide of a CpG endonuclease in mouse lung tumors.Carcinogenesis，2007，28：1499-1503.
25. Alyaqoub FS，Tao LH，Kramer PM，et al.Prevention of mouse lung tumors and modulation of DNA methylation by combinedtreatment with budesonide and R115777 （ZarnestraMT）.Carcinogenesis，2006，27：2442-2447.
26. Greenberg AK，Hu J，Basu S，et al.Glucocorticoids inhibit lung cancer cell growth through both the extracellular signal-related kinase pathway and cell cycle regulators.Am J Respir Cell Mol Biol，2002，27：320-328.
27. Kassel O，Sancono A，Krätzschmar J，et al.Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1.EMBO J，2001，20：7108-7116.
  1. 1. 彭敏，李龍蕓.肺癌的早期診斷.中華內(nèi)科雜志，2003，42：884-886.
  2. 2. Papi A，Casoni G，Caramori G，et al.COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma.Thorax，2004，59：679-681.
  3. 3. Lung Health Study Research Group.Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.N Engl J Med，2000，343：1902-1909.
  4. 4. Pitty TL.Are COPD and lung cancer two manifestations of the same disease? Chest，2005，128：1895-1897.
  5. 5. Skillrud DM，Offord KP，Miller RD.Higher risk of lung cancer in chronic obstructive pulmonary disease：a prospective，matched，controlled study.Ann Intern Med，1986，105：503-507.
  6. 6. Pashko LL，Schwartz AG.Inhibition of 7，12-dimethylbenz[a]anthracene-induced lung tumorigenesis in A/J mice by food restriction is reversed by adrenalectomy.Carcinogenesis，1996，17：209-212.
  7. 7. Wattenberg LW，Estensen RD.Chemopreventive effects of myo-inositol and dexamethasone on benzo[a]pyrene and 4-（methylnitrosoamino）-1-（3-pyridyl）-1-butanone-induced pulmonary carcinogenesis in female A/J mice.Cancer Res，1996，56：5132-5135.
  8. 8. Pereira MA，Li YZ，Gunning WT，et al.Prevention of mouse lung tumors by budesonide and its modulation of biomarkers.Carcinogenesis，2002，23：1185-1192.
  9. 9. Wattenberg LW，Wiedmann TS，Estensen RD，et al.Chemoprevention of pulmonary carcinogenesis by aeosolized budesonide in female A/J mice.Cancer Res，1997，57：5489-5492.
  10. 10. Wattenberg LW，Wiedmann TS，Estensen RD，et al.Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol.Carcinogenesis，2000，21：179-182.
  11. 11. Lipkin M.Biomarkers of increased susceptibility to gastrointestinal cancer：new application to studies of cance prevention in human subjects.Cancer Res，1988，48：235-245.
  12. 12. Estensen RD，Jordan MM，Wiedmann TS，et al.Effect of chemoprevetive agents on separate stages of progression of benzo[a]pyrene induced lung tumors in A/J mice.Carcinogenesis，2004，25：197-201.
  13. 13. Parimon T，Chien JW，Bryson CL，et al.Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease.Am J Respir Crit Care Med，2007，175：712-719.
  14. 14. Miller YE，Keith RL.Inhaled corticosteroids and lung cancer chemoprevention.Am J Respir Crit Care Med，2007，175：636-637.
  15. 15. Lam S，leRiche JC，McWilliams A，et al.A randomized phase IIb Trial of pulmicort turbuhaler（budesonide） in people with dysplasia of the bronchial epithelium.Clin Cancer Res，2004，10：6502-6511.
  16. 16. Keith BD.Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy.BMC Cancer，2008，8：84.
  17. 17. Brody JS，Spira A.State of the art.Chronic obstructive pulmonary disease，inflammation，and lung cancer.Proc Am Thorac Soc，2006，3：535-537.
  18. 18. Pages V，F(xiàn)uchs RP.How DNA lesions are turned into mutations within cells? Oncogene，2002，21：8957-8966.
  19. 19. Barnes PJ.How corticosteroids control inflammation.Br J Pharmacol，2006，148：245-254.
  20. 20. John M，Au BT，Jose PJ，et al.Expression and release of interleukin-8 by human airway smooth muscle cells：inhibition by Th-2 cytokines and corticosteroids.Am J Respir Cell Mol Biol，1998，18：84-90.
  21. 21. Wissink S，van Heerde EC，vand der Burg B，et al.A dual mechanism mediates repression of NF-kappaB activity by glucocorticoids.Mol Endocrinol，1998，12：355-363.
  22. 22. Pereira MA，Tao LH，Wang W，et al.Chemoprevention：mouse colon and lung tumor bioassay and modulation of DNA methylation as a biomarker.Exp Lung Res，2005，31：145-163.
  23. 23. Counts JL，Goodman JI.Hypomethylation of DNA：a possible epigenetic mechanism involved in tumor promotion.Prog Clin Biol Res，1995，391：81-101.
  24. 24. Li L，Tao LH，Lubet RA，et al.Modulation by budesonide of a CpG endonuclease in mouse lung tumors.Carcinogenesis，2007，28：1499-1503.
  25. 25. Alyaqoub FS，Tao LH，Kramer PM，et al.Prevention of mouse lung tumors and modulation of DNA methylation by combinedtreatment with budesonide and R115777 （ZarnestraMT）.Carcinogenesis，2006，27：2442-2447.
  26. 26. Greenberg AK，Hu J，Basu S，et al.Glucocorticoids inhibit lung cancer cell growth through both the extracellular signal-related kinase pathway and cell cycle regulators.Am J Respir Cell Mol Biol，2002，27：320-328.
  27. 27. Kassel O，Sancono A，Krätzschmar J，et al.Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1.EMBO J，2001，20：7108-7116.